Abbott Introduces the Next Generation of Influenza A & B and Strep A Assays with Fastest-Ever Time to Molecular Results

Abbott announced today that the U.S. FDA has cleared its next-generation Influenza A & B 2 and Strep A 2 molecular assays for point-of-care testing. These new assays enable the fastest-ever time to molecular influenza A & B and Strep A results at the point of care